Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis - Scorecard - MDSpire
Advertisement
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn’s disease and ulcerative colitis
Clinical Scorecard: Efficacy and Safety of Deucravacitinib in Inflammatory Bowel Disease: Results from Three Phase 2 Randomized Trials in Crohn's Disease and Ulcerative Colitis Over 12 Weeks
At a Glance
Category
Detail
Condition
Moderately to severely active Crohn’s disease and ulcerative colitis
Key Mechanisms
Selective, allosteric inhibition of tyrosine kinase 2 (TYK2), a downstream mediator of interleukin-23 signaling involved in IBD pathogenesis
Target Population
Adults with moderately to severely active Crohn’s disease or ulcerative colitis
Deucravacitinib is an oral, selective TYK2 inhibitor approved for moderate to severe plaque psoriasis.
Three phase 2 randomized, double-blind, placebo-controlled trials assessed deucravacitinib in Crohn’s disease and ulcerative colitis over 12 weeks.
Primary efficacy endpoints were not met in all studies; deucravacitinib showed no significant clinical benefit over placebo but had a safety profile consistent with prior psoriasis studies.
Guideline-Based Recommendations
Diagnosis
Diagnosis of Crohn’s disease and ulcerative colitis should be based on clinical, endoscopic, and histologic criteria.
Management
Current biologic treatments achieve remission rates of 18%–48%; novel therapies are needed due to nonresponse or loss of response.
Deucravacitinib, despite promising preclinical data, did not demonstrate significant efficacy in phase 2 trials for IBD and is not currently recommended for treatment.
Monitoring & Follow-up
Monitor patients for clinical remission and endoscopic response during treatment.
Safety monitoring should include assessment for adverse events consistent with known TYK2 inhibitor profiles.
Risks
No new safety signals or increased risks of major adverse cardiovascular events, venous thromboembolism, or malignancy were observed with deucravacitinib in IBD trials.
Patient & Prescribing Data
Adults with moderately to severely active Crohn’s disease or ulcerative colitis enrolled in clinical trials
Deucravacitinib was safe and well tolerated but did not demonstrate significant clinical benefit compared to placebo over 12 weeks.
Clinical Best Practices
Consider current approved biologic therapies for IBD with established efficacy.
Recognize the need for novel oral therapies with favorable safety profiles.
Evaluate emerging therapies in well-designed randomized controlled trials before clinical adoption.
by Geert D’Haens, Silvio Danese, Remo Panaccione, David T Rubin, Laurent Peyrin-Biroulet, Katsuyoshi Matsuoka, Edward V Loftus, Taku Kobayashi, Walid Elsharkawi, Rosa Miceli, Samia Ahmed, Yi Luo, Andrew Napoli, John Vaile, Quentin Dornic, Aditya Patel, Stefan Schreiber
The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production
